Navann Ty

Stock Analyst at Exane BNP Paribas

(3.25)
# 2,369
Out of 4,386 analysts
39
Total ratings
55.6%
Success rate
7%
Average return

Stocks Rated by Navann Ty

Organon & Co.
Apr 28, 2026
Downgraded: Hold
Price Target: $15$14
Current: $13.39
Upside: +4.56%
Medline
Jan 12, 2026
Initiated Coverage: Hold
Price Target: $38
Current: $33.80
Upside: +12.43%
Natera
Oct 27, 2025
Upgraded: Hold
Price Target: $28$172
Current: $213.47
Upside: -19.43%
GE HealthCare Technologies
Sep 10, 2025
Reiterated: Buy
Price Target: $92
Current: $64.67
Upside: +42.26%
Phibro Animal Health
Sep 4, 2025
Maintained: Hold
Price Target: $24$37
Current: $31.76
Upside: +16.50%
The Cooper Companies
Jul 22, 2025
Upgraded: Buy
Price Target: $92
Current: $66.79
Upside: +37.75%
Kenvue
May 30, 2023
Initiated Coverage: Hold
Price Target: $28
Current: $17.55
Upside: n/a
SkinHealth Systems
Mar 20, 2023
Upgraded: Hold
Price Target: n/a
Current: $0.6341
Upside: n/a
AbbVie
Dec 8, 2022
Initiated Coverage: Hold
Price Target: $169
Current: $223.07
Upside: n/a
Evolus
Dec 8, 2022
Initiated Coverage: Buy
Price Target: $13
Current: $6.68
Upside: n/a
Maintained: Hold
Price Target: $22$26
Current: $42.45
Upside: n/a
Maintained: Hold
Price Target: $16$11
Current: $15.93
Upside: n/a
Maintained: Hold
Price Target: $232$208
Current: $78.82
Upside: n/a
Initiated Coverage: Buy
Price Target: $200
Current: $232.04
Upside: n/a
Maintained: Buy
Price Target: $39$42
Current: $23.68
Upside: n/a
Maintained: Buy
Price Target: $36.26$51.60
Current: $7.16
Upside: n/a
Initiated Coverage: Hold
Price Target: $10
Current: $33.26
Upside: n/a